

**From:** Do, Yu  
**To:** ["James Maloney"](#)  
**Subject:** Information Request (Response Due by Monday, March 25, 2019): Class 2 Resubmission, BL 125590/0, Immune Globulin Intravenous (Human), 10% Liquid, ADMA Biologics, Inc.  
**Date:** Friday, March 22, 2019 2:16:00 PM  
**Attachments:** [image013.png](#)  
**Importance:** High

---

Dear Mr. Maloney:

We are reviewing your resubmission of September 28, 2018, to BL 125590/0 for Immune Globulin Intravenous (Human), 10% Liquid. We have the following comments and requests for additional information to continue our review:

The following are our proposed languages drafted for a number of Postmarketing Commitments with regard to BL 125590/0:

- ADMA commits to implementing the alert limit of (b) (4) for the (b) (4) prior to the manufacture of the next lot of ASCENIV, 10% IGIV. ADMA will report the implementation as a “Postmarketing Commitment – Status Update.”

Final Report Submission Date: April 30, 2020.

- ADMA commits to reporting the results of bioburden testing of (b) (4) for manufacturing of future lots of ASCENIV, 10% IGIV as a “Postmarketing Commitment – Status Update.”

Final Report Submission Date: April 30, 2020.

- ADMA commits to conducting a comprehensive study of (b) (4) of ASCENIV, 10% IGIV, using the samples held at (b) (4). Both samples will be tested for (b) (4) to generate real-time concordance data. The final study reports will be submitted as a “Postmarketing Commitment – Final Study Report” by April 30, 2020.

Final Report Submission Date: April 30, 2020.

- ADMA commits to conducting a Postmarketing Commitment (PMC) study to evaluate safety concerns related to the amount of excipient PS80 in the final formulation of ASCENIV. These safety concerns include hypotension as well as hepatic and renal impairment. The study will be a Phase 4, non-interventional, prospective, observational 2 arm study in which subjects receive a dose of either ASCENIV or another immune globulin intravenous product every 21 or 28 days for a total of 8 doses per subject.

Final Protocol Submission Date: March 31, 2020

Study Completion Date: June 30, 2023

Final Report Submission Date: December 31, 2023

Please inform us in writing, upon review and internal discussion, if you agree with the proposed languages and due dates. If not, please state accordingly and suggest alternative language(s) or date(s) for our consideration.

The review of this submission is ongoing, and issues may be added, expanded upon, or modified as we continue to review this submission. Please submit your response as an amendment to this file (BL 125590/0) by Monday, March 25, 2019, referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is April 2, 2019.

Please acknowledge receipt of this request and contact me at (240) 402-8343 or [Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov) if you have any questions.

Sincerely,

Yu Do, M.S.  
Regulatory Project Manager  
Office of Tissues and Advanced Therapies  
Center for Biologics Evaluation and Research  
Office of Medical Products and Tobacco  
Food and Drug Administration  
(240) 402-8343  
[Yu.Do@fda.hhs.gov](mailto:Yu.Do@fda.hhs.gov)



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."